Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05434689 · ClinicalTrials.gov registry record · Phase 1

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

A Phase 1 study of Multiple Myeloma, sponsored by University of Alabama at Birmingham.

Active
Registry status
Phase 1
Development phase
80
Enrollment target
6
Study locations

NCT05434689 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 80 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05434689, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
6
Study locations

Study Summary

Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Iberdomide
  • DRUG Carfilzomib

Study Locations (6)

Alabama

  • University of Alabama at Birmingham - Birmingham

North Carolina

  • Duke University - Durham

Ohio

  • Ohio State University Medical College - Columbus

Oregon

  • Oregon Health and Science University - Portland

Tennessee

  • Vanderbilt University Medical College - Nashville

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-01-18
Est. Completion 2026-10
Phase Phase 1

Sponsor

University of Alabama at Birmingham

1,160 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05434689

The ClinicalTrials.gov registry entry for NCT05434689 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT05434689 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, North Carolina, Ohio.

Frequently Asked Questions

What is clinical trial NCT05434689 about?

NCT05434689 is a clinical study titled "COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide". Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to de...

What is the current status of trial NCT05434689?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-01-18. Estimated completion is 2026-10.

What conditions does trial NCT05434689 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05434689?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Iberdomide (DRUG), Carfilzomib (DRUG).

Who is sponsoring clinical trial NCT05434689?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05434689 being conducted?

This trial has 6 study locations across Alabama, North Carolina, Ohio, Oregon, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.